14 articles for DH Slee
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties.

Neurocrine Biosciences
2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A(2A) antagonists with reduced hERG liability.

Neurocrine Biosciences
Development of potent non-carbohydrate imidazole-based small molecule selectin inhibitors with antiinflammatory activity.

Ontogen
N-[6-amino-2-(heteroaryl)pyrimidin-4-yl]acetamides as A2A receptor antagonists with improved drug like properties and in vivo efficacy.

Neurocrine Biosciences
2,6-Diaryl-4-acylaminopyrimidines as potent and selective adenosine A(2A) antagonists with improved solubility and metabolic stability.

Neurocrine Biosciences
Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists.

Neurocrine Biosciences
Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy.

Neurocrine Biosciences
Selection, synthesis, and structure-activity relationship of tetrahydropyrido[4,3-d]pyrimidine-2,4-diones as human GnRH receptor antagonists.

Neurocrine Biosciences
Pyrrolopyrazinedione-based inhibitors of human hormone-sensitive lipase.

Ontogen
Serine/threonine kinase inhibitors

Genentech
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.

Shanghai Institute of Materia Medica
Cholinesterase inhibitors: xanthostigmine derivatives blocking the acetylcholinesterase-induced beta-amyloid aggregation.

University of Bologna
5-aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3).

Glaxosmithkline
Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription.

Smithkline Beecham Pharmaceuticals